Revvity (RVTY) is drawing fresh attention after a jump in options activity, with the September 18, 2026 $50 put ranking among the contracts with the highest implied volatility, and traders signaling expectations for a sizable stock move.
The recent options activity follows a period of strong share price momentum for Revvity, with a 1-day share price return of 1.50%, a 7-day return of 9.75% and a 90-day return of 28.98%, while the 1-year total shareholder return is 37.22%.
Scan how traders’ interest in Revvity compares with other AI-linked plays by checking our curated 75 profitable AI stocks that aren't just burning cash that already have real revenues instead of just promises.
After a sharp move that now puts Revvity at about a 3% premium to the average analyst target, but still around 18% below one intrinsic value estimate, where does a reasonable fair value range really sit for this stock?
Most Popular Narrative: 3.1% Overvalued
Revvity last closed at $124.84 compared with a narrative fair value of $121.07, which frames a modest premium before digging into the growth story behind it.
Ongoing shift in product mix toward higher-margin, software-enabled and consumables-driven offerings (e.g., SaaS Signals, reagents, new IDS i20 platform), along with structural cost actions, are expected to materially expand operating and net margins, with 2026 set to start at a higher 28% operating margin baseline.
Read the complete narrative. Read the complete narrative.
Want to see what kind of earnings and margin path needs to play out for Revvity to justify that premium? The narrative leans heavily on faster profit growth than revenue, a richer mix of recurring software and diagnostics income, and a lower future earnings multiple than many investors might assume.
Result: Fair Value of $121.07 (OVERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, the Revvity narrative can be knocked off course if regulatory pressure in China deepens, or if academic and government funding stays weak for longer.
Find out about the key risks to this Revvity narrative.
Another View: SWS DCF Fair Value For Revvity
The earlier narrative-based fair value pegs Revvity at $121.07 and labels the stock as slightly overvalued. Our DCF model points in a different direction. On those cash flow assumptions, Revvity at $124.84 screens as undervalued against an estimated future cash flow value of $153.02. Which framework do you find more convincing for your own thesis?
Look into how the SWS DCF model arrives at its fair value.
Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Revvity for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 49 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.
Next Steps
With mixed signals in the Revvity story so far, it makes sense to review the full picture for yourself and move promptly while sentiment is still forming. To help, you can scan the 2 key rewards and 1 important warning sign
Looking for more investment ideas beyond Revvity?
If you want a broader watchlist around Revvity, now is a smart moment to line up a few high quality alternatives using focused stock ideas from the Simply Wall St screener.
- Target companies with meaningful upside potential by scanning a curated set of 49 high quality undervalued stocks that pair quality fundamentals with appealing prices.
- Build a portfolio with staying power by reviewing a list of solid balance sheet and fundamentals (51 results) that can better handle tougher conditions.
- Get ahead of the crowd by checking a hand picked group of 18 high quality undiscovered gems that many investors are not tracking yet.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com